FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313455239> ?p ?o ?g. }

• W4313455239 endingPage "1240" @default.
• W4313455239 startingPage "1229" @default.
• W4313455239 abstract "To evaluate the efficacy and safety of janagliflozin, a selective renal sodium-glucose cotransporter-2 inhibitor, as monotherapy in drug-naive Chinese patients with type 2 diabetes mellitus (T2DM).This Phase 3 trial included a 24-week, multicentre, randomized, double-blind, placebo-controlled period, followed by a 28-week extension period. A total of 432 patients with glycated haemoglobin (HbA1c) levels ≥7.0% (53 mmol/mol) and ≤10.5% (91 mmol/mol) were randomized (1:1:1) to receive once-daily placebo, 25 mg or 50 mg janagliflozin. After 24 weeks, patients on placebo were switched and re-randomized (1:1) to 25 mg or 50 mg janagliflozin, whereas patients on janagliflozin maintained the initial therapy. The primary endpoint was change from baseline in HbA1c after 24 weeks.At Week 24, the placebo-adjusted least squares mean changes in HbA1c were -0.80% (95% confidence interval [CI] -0.98% to -0.62%)/-8.7 mmol/mol (95% CI -10.7 mmol/mol to -6.8 mmol/mol) and -0.88% (95% CI -1.06% to -0.70%)/-9.6 mmol/mol (95% CI -11.6 mmol/mol to -7.7 mmol/mol), respectively (P < 0.001 for both). A higher proportion of patients achieved HbA1c <7.0% (53 mmol/mol) with janagliflozin 25 mg and janagliflozin 50 mg compared with placebo (47.2%, 49.3%, and 23.5%, respectively). Both janagliflozin doses significantly decreased fasting plasma glucose, 2-hour postprandial glucose, body weight and systolic blood pressure, as well as increased high-density lipoprotein (HDL) cholesterol and insulin sensitivity compared with placebo (P < 0.05 for all). The trends in improvement of these variables were sustained during the 28-week extension period. Overall incidences of adverse events were 67.8%, 71.5% and 60.7% with janagliflozin 25 mg, janagliflozin 50 mg and placebo, respectively. The incidence of urinary tract infections and genital fungal infections was low. No severe hypoglycaemia or ketoacidosis occurred.Janagliflozin 25 mg and 50 mg monotherapy once-daily effectively improved glycaemic control, reduced body weight and blood pressure, improved HDL cholesterol and insulin sensitivity, and was generally well tolerated." @default.
• W4313455239 created "2023-01-06" @default.
• W4313455239 creator A5000559529 @default.
• W4313455239 creator A5001631757 @default.
• W4313455239 creator A5008500554 @default.
• W4313455239 creator A5018063525 @default.
• W4313455239 creator A5018545990 @default.
• W4313455239 creator A5029035583 @default.
• W4313455239 creator A5030459535 @default.
• W4313455239 creator A5030691366 @default.
• W4313455239 creator A5036949656 @default.
• W4313455239 creator A5037905663 @default.
• W4313455239 creator A5044941285 @default.
• W4313455239 creator A5058736223 @default.
• W4313455239 creator A5063793551 @default.
• W4313455239 creator A5075596275 @default.
• W4313455239 creator A5080804379 @default.
• W4313455239 creator A5081260981 @default.
• W4313455239 creator A5085352453 @default.
• W4313455239 date "2023-01-20" @default.
• W4313455239 modified "2023-10-14" @default.
• W4313455239 title "Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial" @default.
• W4313455239 cites W1973038508 @default.
• W4313455239 cites W2015191704 @default.
• W4313455239 cites W2068171948 @default.
• W4313455239 cites W2096559770 @default.
• W4313455239 cites W2114276479 @default.
• W4313455239 cites W2123946565 @default.
• W4313455239 cites W2137069992 @default.
• W4313455239 cites W2146264128 @default.
• W4313455239 cites W2147602249 @default.
• W4313455239 cites W2172193326 @default.
• W4313455239 cites W2172221709 @default.
• W4313455239 cites W2337454357 @default.
• W4313455239 cites W2572360735 @default.
• W4313455239 cites W2581807473 @default.
• W4313455239 cites W2626446274 @default.
• W4313455239 cites W2769264260 @default.
• W4313455239 cites W2900413769 @default.
• W4313455239 cites W2939222610 @default.
• W4313455239 cites W2944135920 @default.
• W4313455239 cites W2974260792 @default.
• W4313455239 cites W3021305452 @default.
• W4313455239 cites W3088173406 @default.
• W4313455239 cites W3089283105 @default.
• W4313455239 cites W3118613568 @default.
• W4313455239 cites W3200311245 @default.
• W4313455239 cites W4254135372 @default.
• W4313455239 cites W4310296333 @default.
• W4313455239 doi "https://doi.org/10.1111/dom.14971" @default.
• W4313455239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36594724" @default.
• W4313455239 hasPublicationYear "2023" @default.
• W4313455239 type Work @default.
• W4313455239 citedByCount "0" @default.
• W4313455239 crossrefType "journal-article" @default.
• W4313455239 hasAuthorship W4313455239A5000559529 @default.
• W4313455239 hasAuthorship W4313455239A5001631757 @default.
• W4313455239 hasAuthorship W4313455239A5008500554 @default.
• W4313455239 hasAuthorship W4313455239A5018063525 @default.
• W4313455239 hasAuthorship W4313455239A5018545990 @default.
• W4313455239 hasAuthorship W4313455239A5029035583 @default.
• W4313455239 hasAuthorship W4313455239A5030459535 @default.
• W4313455239 hasAuthorship W4313455239A5030691366 @default.
• W4313455239 hasAuthorship W4313455239A5036949656 @default.
• W4313455239 hasAuthorship W4313455239A5037905663 @default.
• W4313455239 hasAuthorship W4313455239A5044941285 @default.
• W4313455239 hasAuthorship W4313455239A5058736223 @default.
• W4313455239 hasAuthorship W4313455239A5063793551 @default.
• W4313455239 hasAuthorship W4313455239A5075596275 @default.
• W4313455239 hasAuthorship W4313455239A5080804379 @default.
• W4313455239 hasAuthorship W4313455239A5081260981 @default.
• W4313455239 hasAuthorship W4313455239A5085352453 @default.
• W4313455239 hasConcept C126322002 @default.
• W4313455239 hasConcept C134018914 @default.
• W4313455239 hasConcept C142724271 @default.
• W4313455239 hasConcept C168563851 @default.
• W4313455239 hasConcept C203092338 @default.
• W4313455239 hasConcept C204787440 @default.
• W4313455239 hasConcept C27081682 @default.
• W4313455239 hasConcept C2777180221 @default.
• W4313455239 hasConcept C2778199505 @default.
• W4313455239 hasConcept C2910068830 @default.
• W4313455239 hasConcept C44249647 @default.
• W4313455239 hasConcept C555293320 @default.
• W4313455239 hasConcept C71924100 @default.
• W4313455239 hasConcept C84393581 @default.
• W4313455239 hasConcept C90924648 @default.
• W4313455239 hasConceptScore W4313455239C126322002 @default.
• W4313455239 hasConceptScore W4313455239C134018914 @default.
• W4313455239 hasConceptScore W4313455239C142724271 @default.
• W4313455239 hasConceptScore W4313455239C168563851 @default.
• W4313455239 hasConceptScore W4313455239C203092338 @default.
• W4313455239 hasConceptScore W4313455239C204787440 @default.
• W4313455239 hasConceptScore W4313455239C27081682 @default.
• W4313455239 hasConceptScore W4313455239C2777180221 @default.
• W4313455239 hasConceptScore W4313455239C2778199505 @default.
• W4313455239 hasConceptScore W4313455239C2910068830 @default.
• W4313455239 hasConceptScore W4313455239C44249647 @default.

• next